COMPARATIVE ANALYSIS OF THE IMPACT OF TRADITIONAL AND MODERN MEDICINES IN GASTRITIS

173 Volume 5, Issue 10: Special Issue (EJAR) ISSN: 2181-2020 MPHAPP THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE “MODERN PHARMACEUTICS: ACTUAL PROBLEMS AND PROSPECTS” TASHKENT, OCTOBER 17, 2025 in-academy.uz COMPARATIVE ANALYSIS OF THE IMPACT OF TRADITIONAL AND MODERN MEDICINES IN GASTRITIS Ibragimova G.B. Suyunov N.D. Tashkent Pharmaceutical Institute, Tashkent city, Republic of Uzbekistan e-mail: [email protected] https://doi.org/10.5281/zenodo.17332472 Relevance: gastritis is an inflammation of the gastric mucosa, which can occur in acute or chronic forms. Its causes include Helicobacter pylori infection, acid hyper secretion, and other contributing factors. Since the 1990s, traditional proton pump inhibitors, e.g., omeprazole have been the standard therapy for gastritis and Helicobacter pylori eradication. However, in recent years, the global rate of antibiotic resistance has reached 20–30%, and long-term use of proton pump inhibitors has been associated with certain risks, such as gastric atrophy and vitamin deficiencies. As an alternative, modern potassium-competitive acid blockers, e.g., vonoprazan have been introduced. These agents inhibit gastric acid secretion more rapidly and for longer durations, potentially improving Helicobacter pylori eradication efficacy by 10–20%. According to the findings of studies conducted between 2023 and 2025, the role of potassium-competitive acid blockers in the treatment of gastritis is becoming increasingly significant. In particular, their advantages in improving the efficacy of Helicobacter pylori eradication and reducing the progression of gastric mucosal injury have been scientifically demonstrated. Therefore, potassium-competitive acid blockers are recommended in clinical practice as an optimal therapeutic option for patients and are expected to become a main therapeutic approach in the coming years for the treatment of gastritis and Helicobacter pylori-related diseases. Purpose of the study: gastritis (acute and chronic forms) in treatment traditional proton pump inhibitors proton pump inhibitors and between modern potassium-competitive acid blockers potassium-competitive acid blockers efficiency and Systematic safety monitoring comparison. Materials and methods: this study was based on a systematic literature review and metaanalysis, including randomized clinical trials and meta-analyses retrieved from PubMed and Google Scholar databases from 2020–2025. Results: the results of the meta-analysis showed the superiority of potassium-competitive acid blockers over proton pump inhibitors. The pooled Risk Ratio for Helicobacter pylori eradication efficacy was 1.17, (95% Confidence interval: 1.11–1.22, I² = 28%), indicating that potassiumcompetitive acid blockers were 17% more effective. The Odds Ratio for the rate of peptic ulcers and gastritis was 1.25 (95% Confidence interval: 1.08–1.45, I² = 40%), and accelerated mucosal regeneration in atrophic changes. There was no difference in side effects (diarrhea, headache) (Risk Ratio = 1.01, 95% Confidence interval: 0.88–1.16). Potassium-competitive acid blockers were more effective in the acute and chronic subgroups of gastritis resistant more effective in forms Risk Ratio = 1.18. Table Proton pump inhibitors and potassium-competitive acid blockers drugs gastritis results of a meta-analysis of effectiveness 174 Volume 5, Issue 10: Special Issue (EJAR) ISSN: 2181-2020 MPHAPP THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE “MODERN PHARMACEUTICS: ACTUAL PROBLEMS AND PROSPECTS” TASHKENT, OCTOBER 17, 2025 in-academy.uz Meson Proton pump inhibitors Potassiumcompetitive acid blockers Risk Ratio/ Odds Ratio, 95% Confidence interval I² (%) Helicobacter pylori eradication 78.0% 92.0% 1.17 (1.11–1.22) 28 Injury how much 76.0% 89.0% 1.25 (1.08–1.45) 40 Side effects 13.0% 13.2% 1.01 (0.88–1.16) 15 Conclusions: in gastritis, potassium-competitive acid blockers show statistical and clinical superiority over proton pump inhibitors in acid suppression and Helicobacter pylori eradication, which serves to stop inflammation and reduce the risk of complications. Recommendation: in firstline therapy, a potassium-competitive acid blockers-based triple regimen «Vonoprazan 20 mg + amoxicillin + clarithromycin, 14 days» is preferred; in Uzbekistan, taking into account resistance, it should be combined with a bismuth-based regimen.